Market Research Reports

Non Small Cell Lung Cancer Therapeutics Market: (By Drug Class: Angiogenesis Inhibitor, EGFR Inhibitor, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, and PD-1/PD-L1 Inhibitor): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023

94pages
Published Date: 2015-11-26

Description


This report on the non-small cell lung cancer (NSCLC) Therapeutics market studies the current and future prospects of the global market. Non-small cell lung cancer is a type of lung cancer which accounted 85-90% of all lung cancers. There are three major subtypes of NSCLC namely squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. NSCLC is relatively insensitive to chemotherapy compared to small cell lung cancer. Increasing awareness along with incidence rate are expected to propel the global non-small cell lung cancer therapeutics market.

The NSCLC market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global NSCLC therapeutics market with respect to the segments based on the type of drug class, and their geographic analysis. A detailed qualitative analysis of driving and restraining factors for the market growth and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global NSCLC therapeutics market.

Based on drug class, the NSCLC therapeutics market has been segmented into six major categories: angiogenesis inhibitor, epidermal growth factor receptor blocker, kinase inhibitor, microtubule stabilizer, folate antimetabolites, and PD-1/ PD-L1 inhibitor. The market segments have been extensively analyzed based on usefulness, efficacy, revenue, and geographical coverage. The market size and forecast in terms of USD million for each segment has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year.

Geographically, the global NSCLC therapeutics market has been categorized into four major regions and the key countries in the respective region: North America (U.S., Canada), Europe (U.K., Germany, Rest of Europe), Asia Pacific (Japan, China, and Rest of Asia Pacific), and Rest of the World. The market size and forecast for each of these regions and the mentioned countries has been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. The research study also covers the competitive scenario in these regions.

The report also profiles major players in the global NSCLC therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include Genentech, Inc. ( a Roche Company), Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Pfizer, Inc., Novartis AG, Astra Zeneca plc, and Celgene Corporation.

The global non-small cell lung cancer therapeutics market is segmented as follows:

  • Global Non-Small Cell Lung Cancer Therapeutics Market, by Drug Class, 2013–2023 (US$ Mn)
    • Overview
    • Angiogenesis Inhibitor
      • Avastin (bevacizumab)
      • Cyramza (Ramucirumab)
    • Epidermal Growth Factor Receptor Blocker
      • Tarceva (erlotinib)
      • Gilotrif (afatinib)
      • Iressa (gefitinib)
    • Kinase Inhibitor
      • Xalkori (crizotinib)
      • Zykadia (ceritinib)
    • Microtubule Stabilizer
      • Abraxane (paclitaxel protein bound)
      • Docetaxel
    • Folate Antimetabolites
      • Alimta (pemetrexed)
    • PD-1/ PD-L1 Inhibitor
      • Opdivo (nivolumab)
      • Keytruda (pembrolizumab)
  • Pipeline Analysis: Global Non-Small Cell Lung Cancer Therapeutics Market
    • Overview
    • Late Stage (Phase III) Forecast for Phase III Drugs Post Expected Launch till 2023 (US$ Mn)
      • Avelumab - Pfizer, Inc.
      • MPDL3280A - Roche
      • MEDI4736 - AstraZeneca
      • Abemaciclib - Eli Lilly and Company
      • Others
    • Early Stage (Phase I and II) (Qualitative Analysis - Tabular representation)
  • Global Non-Small Cell Lung Cancer Therapeutics Market, by Geography, 2013–2023 (US$ Mn)
    • Overview
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • Rest of Europe
    • Asia Pacific
      • Japan
      • China
      • Rest of Asia Pacific
    • Rest of the World

Table of Contents



1. Preface
    1.1. Report Description
    1.2. Research Methodology
    1.3. Market Segmentation

2. Executive Summary
    2.1. Market Snapshot
    2.2. Comparative Analysis: Non-Small Cell Lung Cancer Market, by Geography, 2014 & 2023 (Value %)

3. Non-Small Cell Lung Cancer Market Overview
    3.1. Introduction
    3.2. Treatment Guidelines and Disease Management
    3.3. Companion Diagnostics: Overview
    3.4. Regulatory Scenario
    3.5. Market Dynamics
          3.5.1. Drivers
          3.5.2. Restraints
          3.5.3. Opportunities
    3.6. Event Impact Analysis, 2013 - 2023
    3.7. Market Attractiveness Analysis of Global Non-Small Cell Lung Cancer Market, by Geography, 2014
    3.8. Competitive Landscape
3.8.1. Market Share Analysis of Key Players, 2014 (Value %)

4. Market Segmentation – By Drug
    4.1. Overview  
    4.2. Global Non-Small Cell Lung Cancer Market Revenue, by Drug Class, 2013–2023 (US$ Mn)
          4.2.1. Global Angiogenesis Inhibitor Market Revenue, 2013–2023 (US$ Mn) and Analysis
          4.2.2. Global EGFR Blockers Market Revenue, 2013–2023 (US$ Mn) and Analysis
          4.2.3. Global Kinase Inhibitor Market Revenue, 2013–2023 (US$ Mn) and Analysis
          4.2.4. Global Microtubule Stabilizer Market Revenue, 2013–2023 (US$ Mn) and Analysis
          4.2.5. Global Folate Antimetabolites Market Revenue, 2013–2023 (US$ Mn) and Analysis
          4.2.6. Global PD-1/PD-L1 Inhibitor Market Revenue, 2013–2023 (US$ Mn) and Analysis

5. Pipeline Analysis
    5.1. Overview 
    5.2. Late Stage (Phase III) 
          5.2.1. Avelumab - Pfizer, Inc.
          5.2.2. MPDL3280A - Roche
          5.2.3. MEDI4736  - AstraZeneca
          5.2.4. Abemaciclib – Eli Lilly and Company 
          5.2.5. Others
    5.3. Early Stage (Phase I and II) (Qualitative Analysis - Tabular representation)

6. Market Segmentation – By Geography
    6.1. Introduction
    6.2. Global Non-Small Cell Lung Cancer Market Revenue, by Region, 2013–2023 (US$ Mn)    
    6.3. North America Non-Small Cell Lung Cancer Market Revenue, by Country, 2013–2023 (US$ Mn)
          6.3.1. U.S. Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
          6.3.2. Canada Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
    6.4. Europe Non-Small Cell Lung Cancer Market – Revenue, by Country, 2013–2023 (US$ Mn)
          6.4.1. U.K. Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
          6.4.2. Germany Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
          6.4.3. Rest of Europe Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
    6.5. Asia Pacific Non-Small Cell Lung Cancer Market Revenue, by Country, 2013–2023 (US$ Mn)
          6.5.1. Japan Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
          6.5.2. China Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
          6.5.3. Rest of APAC Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
    6.6. Rest of the World Non-Small Cell Lung Cancer Market Revenue, by Country, 2013–2023 (US$ Mn)

7. Recommendations
    7.1. Recommendation 1: Research and Development Initiatives to Penetrate the Market
    7.2. Recommendation 2: Investment in Emerging Economy 

8. Company Profiles
    8.1. Astra Zeneca PLC
    8.2. Boehringer Ingelheim
    8.3. Bristol-Myers Squibb
    8.4. Celgene Corporation
    8.5. GlaxoSmithKline PLC
    8.6. Eli Lilly & Co.
    8.7. Pfizer, Inc.
    8.8. Genentech, Inc. (a Roche company)
    8.9. Sun Pharmaceutical Industries Ltd.

Free Market Analysis


NSCLC, often the most dreaded of all types of lung cancer, is highly likely to metastasize into the bones and other tissues, making it difficult to detect and treat. NSCLC accounts for 90% of all lung cancer cases. Drugs used in the treatment of NSCLC range from regular regimens to targeted therapies. The drugs are based on simple chemistries to highly advanced complex protein. The market is witnessing strong growth due to high awareness among the population through government initiatives. Moreover, the drugs for NSCLC are given swift approvals by regulatory bodies and grants for research. This has led to new generation of drugs being introduced in the NSCLC market.

The major classes of drugs under NSCLC are angiogenesis inhibitor, EGFR blocker, kinase inhibitor, microtubule stabilizer, folate antimetabolites, and PD-1/PD-L1 inhibitors. The angiogenesis inhibitor segment dominated the market in 2014. High efficacy, targeted therapies, and increasing demand in major geographies such as Europe, the U.S., and Japan are attributed to the dominance of the angiogenesis inhibitor segment in the NSCLC therapeutics market. Zykadia is expected to witness the highest growth rate during the forecast period, followed by Opdivo. 

Geographically, the NSCLC market segmented into four major regions: North America, Europe, Asia Pacific (APAC), and ROW. North America dominated the global NSCLC therapeutics market in 2014 due to the presence of modern health care infrastructure and an efficient U.S. government system. However, APAC is anticipated to expand at the fastest CAGR during the forecast period. Factors such as increasing population, greater awareness about NSCLC, and growing number of government projects related to lung, cancer, tobacco, and their respective interventions would boost the growth of the market in APAC during the forecast period.

The NSLCLC therapeutics market exhibits intense competition among existing players. The market is fragmented, characterized by the presence of both generic and branded companies. Major players operating in the NSCLC market are Genentech, Inc. ( a Roche Company), Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Pfizer, Inc., Novartis AG, AstraZeneca plc, and Celgene Corporation. 

global-non-small-cell-lung-cancer-therapeutics-market


To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Report tailored as you need

If you feel this report needs customization, feel free to contact us. Our team of expert analyst can fulfil your requirements.

CUSTOMIZE REPORT

Upcoming Report

Payment
Copyright @ Transparency Market Research